MHT increases invasive breast cancer

In the Women's Health Initiative (WHI), combined estrogen-progestin replacement therapy was associated with a significant increase in invasive breast cancer (unadjusted HR 1.24, 95% CI 1.01-1.54) when compared with placebo.

MHT: menopausal hormone therapy; HR: hazard ratio.

Data from: Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003; 289:3243.

Graphic 69819 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟

خرید پکیج

MHT increases invasive breast cancer